Barclays
IPSC icon

Barclays’s Century Therapeutics IPSC Stock Holding History

Barclays’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$89.2K Buy
52,168
+27,468
+111% +$56.3K ﹤0.01% 4355
2026
Q2 		$60.5K Sell
24,700
-95,532
-79% -$218K ﹤0.01% 4252
2026
Q1 		$272K Buy
120,232
+120,231
+12,023,100% +$253K ﹤0.01% 3520
2025
Q4 		$1 Hold
1
– – ﹤0.01% 5191
2025
Q3 		$0 Sell
1
-12,196
-100% -$6.58K ﹤0.01% 5605
2025
Q2 		$6.82K Sell
12,197
-35,012
-74% -$18.8K ﹤0.01% 4946
2025
Q1 		$22.5K Sell
47,209
-23,266
-33% -$17.5K ﹤0.01% 4775
2024
Q4 		$71.2K Buy
70,475
+8,530
+14% +$11.6K ﹤0.01% 4667
2024
Q3 		$106K Buy
61,945
+45,797
+284% +$89.7K ﹤0.01% 4558
2024
Q2 		$41.2K Sell
16,148
-315
-2% -$996 ﹤0.01% 4283
2024
Q1 		$68.8K Sell
16,463
-15,721
-49% -$66.5K ﹤0.01% 4543
2023
Q4 		$107K Buy
32,184
+28,035
+676% +$51.1K ﹤0.01% 4624
2023
Q3 		$8.3K Sell
4,149
-520
-11% -$1.38K ﹤0.01% 4329
2023
Q2 		$14.8K Sell
4,669
-5,616
-55% -$18.1K ﹤0.01% 4177
2023
Q1 		$35.7K Buy
10,285
+4,877
+90% +$21.4K ﹤0.01% 4523
2022
Q4 		$27.7K Buy
5,408
+4,554
+533% +$43K ﹤0.01% 4745
2022
Q3 		$8K Sell
854
-156
-15% -$1.64K ﹤0.01% 4390
2022
Q2 		$8K Sell
1,010
-1,805
-64% -$17.7K ﹤0.01% 4693
2022
Q1 		$36K Buy
+2,815
New +$37.3K ﹤0.01% 4241

Other funds holding IPSC

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
PM
Parametrica Management Wanchai, Hong Kong $142M AUM 113.92% 1-Year Est. Return
Quadrant Private Wealth Management
Quadrant Private Wealth Management Center Valley, Pennsylvania $753M AUM 13.49% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Xponance
Xponance Philadelphia, Pennsylvania $17.2B AUM 36.34% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays's IPSC Position: Q3 2026 in Review

Barclays increased its Century Therapeutics (IPSC) stake by 111% in Q3 2026, buying an estimated $56.3K and bringing the position to 52,168 shares worth $89.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4355.

Barclays first reported a position in IPSC in Q1 2022 and has held it in 19 quarters since. The position peaked at $272K in Q1 2026. 19 funds tracked by Wall St. Rank hold IPSC as of Q3 2026.

  • Barclays held 52,168 shares of Century Therapeutics worth $89.2K as of Q3 2026.
  • Barclays bought 27,468 Century Therapeutics shares in Q3 2026, an estimated $56.3K.
  • Century Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4355 holding.
  • Barclays first reported a position in Century Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Century Therapeutics position peaked at $272K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.